Blood test accurately detects Alzheimer's in Asian populations

A new study has found that a blood test can accurately detect Alzheimer's disease in Asian populations. The research was published in the journal Alzheimer's & Dementia. It highlights the use of plasma p-tau217 as a blood-based biomarker. This test can identify abnormal brain beta-amyloid levels, which are linked to Alzheimer's. The study shows that the blood test is effective even among individuals with cerebrovascular disease, common in Asian communities. Dr. Mitchell Lai led the research at the National University of Singapore, collaborating with international experts. The findings suggest that early detection of Alzheimer's could improve patient care and management. Plasma p-tau217 is a significant tool because it can predict cognitive decline. Higher levels of this biomarker are associated with faster deterioration in mental abilities. The researchers believe it could transform how Alzheimer's is diagnosed, making the process easier and more accessible. Using plasma p-tau217 could allow for earlier detection than current methods, like PET scans. This blood test is less invasive and more affordable, which would help increase screening in clinical settings. It also allows doctors to categorize patients based on their risk levels for Alzheimer’s disease. Experts are optimistic about the potential of this blood test. Professor Christopher Chen from the National University Health System remarked that it could be a game-changer in diagnosing Alzheimer's for those with a high burden of cerebrovascular disease. The researchers plan to expand their study to explore more biomarkers for better diagnosis and treatment strategies in the future.